MedTrace Logo

Study to Evaluate the Amount of Medications That May be Removed From the Body During Plasmapheresis

NCT00203281 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-10-21

No results posted yet for this study

Summary

Based on the limited amount of experience with plasmapheresis and CytoGam concomitant use, the researchers seek to evaluate the pharmacokinetics (drug absorption, distribution, and elimination) of this therapy. The researchers are also interested in evaluating the pharmacokinetics of the various immunosuppressant medications that patients will receive such as tacrolimus, mycophenolate mofetil and daclizumab.

Conditions

  • Kidney Transplantation
  • Plasmapheresis

Interventions

DRUG

tacrolimus

DRUG

mycophenolate mofetil

DRUG

daclizumab

DRUG

intravenous immune globulin

PROCEDURE

plasmapheresis

Sponsors & Collaborators

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Mark Chaballa, PharmD · Thomas Jefferson University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00203281 on ClinicalTrials.gov